Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer.
Fiche publication
Date publication
mai 2024
Journal
Clinics and research in hepatology and gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier, Pr MANFREDI Sylvain
Tous les auteurs :
Cazeneuve N, Bouché O, Leger J, Borg C, Labbe-Devilliers C, Lucidarme O, Tasu JP, Manfredi S, Aubé C, Trillaud H, Manzoni P, Marcus C, Terrebonne E, Douillard JY, Chautard R, Lobet S, Scotto B, Bleuzen A, Lecomte T
Lien Pubmed
Résumé
Visceral fat produces angiogenic factors such as vascular endothelial growth factor that promote tumoral growth. However, its influence on outcome for patients with advanced cancer treated with anti-angiogenic agents is controversial.
Mots clés
Bevacizumab, Colorectal cancer, Prognosis, VEGF, Visceral fat
Référence
Clin Res Hepatol Gastroenterol. 2024 05 23;48(7):102380